Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06342947 · ClinicalTrials.gov registry record · Phase 2
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
A Phase 2 study of Nonalcoholic Steatohepatitis and NASH, sponsored by Aligos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 20
- Study locations
NCT06342947: Completed Phase 2 study of Nonalcoholic Steatohepatitis and NASH, sponsored by Aligos Therapeutics.
NCT06342947 is a Phase 2 study of Nonalcoholic Steatohepatitis and NASH that has completed, run by Aligos Therapeutics. The registered enrollment target is 102 participants, below the 699-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06342947, a Phase 2 study of Nonalcoholic Steatohepatitis and NASH, has completed, sponsored by Aligos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.
Primary Outcome
Percent relative change from baseline in liver fat content by MRI-PDFF at Week 12
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALG-055009
Study Locations (20)
Florida
- Aligos Clinical Study Site 26 - Bradenton
- Aligos Clinical Study Site 25 - Clearwater
- Aligos Clinical Study Site 39 - Fort Myers
- Aligos Clinical Study Site 2 - Maitland
- Aligos Clinical Study Site 22 - Ocoee
- Aligos Clinical Study Site 32 - Port Orange
- Aligos Clinical Study Site 38 - Sarasota
- Aligos Clinical Study Site 31 - The Villages
- Aligos Clinical Study Site 3 - Viera
- Aligos Clinical Study Site 30 - Winter Park
California
- Aligos Clinical Study Site 35 - Chula Vista
- Aligos Clinical Study Site 1 - Lincoln
- Aligos Clinical Study Site 37 - Poway
- Aligos Clinical Study Site 10 - Rialto
Arizona
- Aligos Clinical Study Site 18 - Chandler
- Aligos Clinical Study Site 15 - Peoria
- Aligos Clinical Study Site 17 - Tucson
Georgia
- Aligos Clinical Study Site 23 - Athens
Kansas
- Aligos Clinical Study Site 12 - Topeka
Kentucky
- Aligos Clinical Study Site 29 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2024-09-09 |
| Phase | Phase 2 |
What the finished NCT06342947 record still lists
NCT06342947 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 699-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06342947 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06342947 about?
NCT06342947 is a clinical study titled "ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)". This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.
What is the current status of trial NCT06342947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2024-04-01. Estimated completion is 2024-09-09.
What conditions does trial NCT06342947 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis, NASH, Metabolic Dysfunction-associated Steatohepatitis, MASH.
What interventions are being tested in trial NCT06342947?
The interventions under investigation include: Placebo (DRUG), ALG-055009 (DRUG).
Who is sponsoring clinical trial NCT06342947?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06342947 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06342947's enrollment target sits among peer trials
102 19th of 30 higher than 12 of 30 other Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
ACTIVE NOT RECRUITING · Phase 2
-
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI